intevac inc ivac hold pt pace major custom move make us concern inflect growth may
come fruition downgrad hold analyst nehal chokshi full summari
inc hold pt downgrad hold valuat in-lin believ posit
price stock maintain pt analyst stephen anderson full summari
inc buy pt strong rais price due much higher valuat best
 reiter buy analyst nehal chokshi full summari
 buy pt introduc ep estim rais price
custom inc buy pt stand-alon ep spin-off bankmobil on-schedul
reiter buy rate price target analyst michael diana full summari
inc buy pt biolif continu grow come warrant analyst jason
cytori inc cytx buy pt liposom doxorubicin move toward approv eu analyst jason
inc buy pt strong result guidanc rais estim price
 reiter buy analyst michael diana full summari
pluristem inc psti buy pt clear emerg use treat acut radiat exposur
whiteston reit buy pt proxi fight favor director nomine reiter buy rate
corpor event call maxim salesperson inform
annual summer confer host vendetti chokshi jang abwn bhtg
inc cover confer call presid scott colosi senior director
ir/financi report tonya robinson mon may
inc cover confer call cfo kate jaspon presid david
cover ndr boston cfo golder wed jun
annual summer confer host vendetti chokshi jang abwn bhtg
corpor ctrl cover chokshi ndr boston ct nyc cfo mark novakovich tues-thur
identiv inc host chokshi group dinner nyc ceo stephen humphrey cfo sarah wallach
annual silicon valley bu tour host chokshi tue juli
annual summer confer host vendetti chokshi jang abwn bhtg
navig hold ltd nvg cover jang group luncheon nyc ceo david butter tue may
annual summer confer host vendetti chokshi jang abwn bhtg
downgrad hold valuat in-lin
believ posit price stock maintain pt
downgrad share texa roadhous hold buy
follow releas mostli in-lin march though maintain
report in-lin ep blend comp beat
consensu
comp june date also strong start
read though lap weaker april comp
share trade revis ep estim
near compani long-term averag forward price-to-earnings
light year-to-d gain share believ potenti
posit risk balanc current share price take
factor account
ep actual vs maxim street
revenu actual vs maxim street
comp actual blend vs maxim blend street
restaurant-level ebitda margin actual vs maxim
street
oper margin actual vs maxim street
june to-dat comp actual vs maxim street
ep manag provid full-year ep guidanc vs maxim pre-
releas vs street revis ep estim
comp reiter posit same-restaur sale vs pre-releas estim
maxim blend street revis comp estim
food cost inflat revis flat y/i
labor cost inflat unchang mid-single-digit inflat
new unit growth unchang net new company-own unit
downgrad hold believ share valu fairli
unchang price target base assumpt combin
comp growth market share gain stringent cost control benign commod
cost power annual ep growth next month
howev yesterday close price less away price
target believ potenti upsid top-lin growth
balanc potenti bottom-lin risk notabl increas inflationari risk
arriv price target multipli forward price-to-earnings multipl target
ep estim also correspond forward ev/ebitda ratio
think investor seek upsid casual dine consid share
dribuy among top sector pick
click full note
pace major custom move make us
concern inflect growth may come fruition
downgrad hold
result in-lin guidanc cut thin film equip
odlc differ odlc signific concern pace
major custom move indic potenti never
come fruition
valid top smartphon oem believ huawei privat
indic signific valu odlc attain henc util ev/
multipl price target lower
result in-lin guidanc cut thin film equip
photon ivac report revenu ep high-
end prior guidanc thin film equip tfe
revenu outperform expect strong upgrad
activ revenu miss expect
q/q declin product revenu vs prior expect q/
 result in-lin manag cut revenu guidanc
least y/i growth y/i declin tfe revenu guidanc cut
least y/i y/i photon revenu guidanc
chang flat y/i y/i reason cut photon
larg due reduct joint strike fighter program requir ivac night
vision camera though believ manag reason view cut shift
demand reason cut thin film equip result key
coverglass odm partner truli opto-electron privat put hold plan put
new line util ivac vertex tool major custom believ
could requir vertex tool multi-year period offici requir chang
ivac odlc optic diamond like carbon ivac dub odlc
reduc revenu guidanc ivac also lower gm guidanc midpoint
also reduc annual opex result
guidanc paramet reduc ep estim
loss
odlc differ odlc signific concern pace
major custom move indic potenti never
come fruition odlc higher durabl anti-scratch film rel
predecessor odlc addit higher durabl ivac
work custom integr film stack odlc film stack
includ decor coat huawei util
reflect coat back creat color hard anti-reflect coat
optic transpar like front-sid protect ivac note ramp
custom believ smartphon oem odm one top
smartphon oem samsung predic qualif
odlc film stack manag note custom evalu
odlc film stack year final review march led new
specif new specif requir thicker underlay resist sharp point
impact still maintain optic transpar expect
signific develop believ work ivac come
top pace compani would move implement ivac odlc film
stack would much faster view rel slow pace qualifi
ivac film stack slowli chang set requir sign signific
risk exist major custom signific potenti never come fruition
valid top smartphon oem believ huawei indic signific
valu odlc attain henc util ev/ multipl
month price target lower back away
prior view ivac second vertex custom ramp smartphon ivac
odlc coat continu believ odlc film signific valu
smartphon oem evidenc top smartphon oem believ huawei see
march report adopt ivac odlc film stack decor color coat
smartphon back howev rather expect explos growth
comfort project modest growth help swing ivac
back profit like continu slow growth thereaft given perspect
will util ev/ multipl price target result
reduc price target prior valuat base
ev/ni prior ep estim
click full note
favor rais pt reiter buy
rmbl report earn yesterday better-than-expect revenu
vs estim guidanc rang
gross margin report gm vs estim
signific margin enhanc stem favor vehicl process
econom dealer auction partner network give us confid
lt gm achiev prior estim long-term
expect gm rais flow oper profit
result rais target
revenu beat attribut success acquir vehicl consum
expect continu experi rapid growth rmbl report
revenu q/q midpoint guidanc gm
q/q significantli estim ep loss
revenu upsid driven success vehicl acquisit side
rmbl receiv customer-submit apprais q/q
apprais apprais accept seller
compani report impress day inventori outstand demonstr
abil effect turn acquir vehicl quickli either auction dealer
consum channel still gener profit compani current pace month-
over-month doubl apprais submit coupl abil sell inventori
quickli either three sale channel lead us believ compani
nearli doubl revenu q/q rais revenu estim
repres growth q/q increas
revenu estim
gm rise q/q despit sale mix consum give us
confid higher long-term gross margin achiev rmbl gross
margin increas attribut favor vehicl process econom
dealer auction partner network estim cost declin
q/q expect rmbl continu pare cost compani
recent increas number auction locat two
benefit freight econom well recondit rate compar dealer
recondit fee regardless asp gross profit per unit remain constant
believ compani valu abil sell profit driven servic
acquir motorcycl via internet save consum time process
view rel fix across motorcycl see figur initi
date april view mix shift toward consum sale channel
primari margin enhanc sale consum account sale
gpu excl process transient cost sale dealer
auction channel account remaind gpu yield blend gross
profit per motorcycl sold estim process cost freight
recondit per unit sold transient cost freight unsold
vehicl inventori reserv sold time expect sale mix
split evenli consum dealers/auct give us
confid rais lt gm rais gm
estim also rais sg estim better reflect true oper
structur expect lt sg includ compens advertis profession
fee technolog develop gener administr expens
compris termin period prior estim
reiter buy rate rais price target reflect
continu sale ramp favor gross margin structur therefor
mix-shift navig away hd motorcycl toward lower asp model
away dealer sale toward consum sale expect higher blend gm
price target base dcf analysi assum long-term market
share gross margin oper margin
click full note
introduc ep estim rais price
 best idea among bank
listen recent earn confer call struck
larg cost-sav opportun avail see
integr astoria financi bank roughli equal size
one statement found particularli strike manag
intend keep expens level target level
million exclud amort intang produc
introduc ep estim incorpor
million oper expens page updat earn model
base new ep estim rais price target
new price target equat new ep estim
in-line closest peer texa capit bancshar inc
p/e best-in-class mid-cap bank
integr opportun
view depress share price repres rare opportun
share bank larg integr opportun
manag team track record take advantag
opportun best idea
acquisit astoria octob complet acquisit
astoria financi nearli doubl size dramat increas presenc
long island area favor demograph give top six
market share among region bank new york citi
integr opportun includ close branch schedul
possibl equal number sale astoria headquart build
alreadi announc system integr earn confer
call manag indic fifth sixth inning final everyth
go system integr perspect suggest us
still materi opportun
reiter buy rate next four quarter expect stock price
appreci new price target dividend yield
result estim total return
click full note
stand-alon ep spin-off bankmobil
on-schedul reiter buy rate price target
report ep commun busi bank
segment stand-alon post-spin-off
manag reiter guidanc ep cbb/stand-alon
close spin-off bankmobil
introduc non-gaap ep estim cbb/stand-
alon high end manag guidanc
subtract midpoint manag previou estim
per share valu bankmobil price target leav
valuat cbb/stand-alon would support
price target
valuat equat non-gaap ep estim
cbb/stand-alon in-line price-to-earnings multipl
high-qual small-cap bank follow
result summari report ep includ bankmobil
versu consensu view meaning number
meaning number relat commun busi bank segment
stand-alon post-spin-off ep
clean quarter non-recur item though note
averag balanc sheet unders
unders averag balanc sheet reason kept balanc sheet
billion asset decemb preserv durbin act
qualif june grew balanc sheet throughout
restrictively-low start point one consequ lower averag
earn asset anoth consequ lower net interest margin nim due
mix-shift toward lower-yield invest secur ad much
quickli loan inde nim linked-quart though
exclud impact mix-shift fewer prepay fee core nim
accord manag
non-gaap ep high-end manag
guidanc rang manag guidanc includ
growth total asset net interest margin nim
effici ratio mid-to-high effect tax rate
bank team new market chicago washington dc new bank
team exist market new york citi pennsylvania/new jersey
abl gener core deposit help reliev nim pressur togeth
continu strong credit qualiti expens control posit
produc solid earn
financi perform bankmobil meaning sharehold
impact price success bankmobil spin-off
note bankmobil prepar launch number white label third-parti
rebrand card loan product soon improv bankmobil financi
perform bankmobil busi season like unprofit
pre-spin mention close bankmobil spin-off expect
reiter buy rate next four quarter expect stock price
appreci price target
click full note
strong rais price due much
higher valuat best compar reiter buy
result strong adjust ebitda beat consensu
ep beat consensu
manag chang full-year guidanc million
adjust ebitda ep rais
estim modestli partli higher market expens
case ep higher effect tax rate manag initi
howev rais price target
valuat best close compar
 buy increas materi late
sustain profit record enova demonstr us
way sustain profit capabl strong loan
growth along solid credit qualiti
result summari yesterday close report adjust
ebitda million versu consensu million ep versu
consensu regard strong quarter loan growth versu
busi season best comparison year-ago
quarter revenu growth versu attract new
custom versu new custom drive futur growth
mani becom repeat custom much profit low/no market
expens lower loan loss provis reliabl credit histori
credit qualiti regard credit qualiti stabl as-expect net charge-
off revenu compar percentag past-
due loan arguabl best indic futur credit qualiti compar
addit vintag loss curv remain
prior year
manag guidanc manag reiter guidanc
revenu million adjust ebitda million net incom
million ep guidanc effect tax rate
rais due impact new tax law
rais estim modestli new ebitda estim
million million new ep estim
estim incorpor manag guidanc page updat
rais price target regard on-line non-prim competitor
best close compar enova valuat
increas materi late price target ev/ebitda
multipl would versu enova price-to-earnings multipl would
versu enova view discount reason
time expect second year posit core net incom
wherea enova profit sinc format howev
way sustain profit view ep higher
core ep full-year
reiter buy rate next four quarter expect stock price
appreci price target
click full note
liposom doxorubicin move toward approv eu
cytori releas updat liposom doxorubicin includ
approv plan europ manufactur
manufactur liposom formul conduct cytori
texas-bas facil fill/finish perform us bryllan
commercial-scal contract manufactur cytori intend seek approv
eu first expect follow complet stabil test
compani posit file later earli
month review period launch partner
market opportun caelyx/doxil gener per year
europ gener reach market larg liposom
doxorubicin difficult manufactur like biosimilar
cytori right manufactur place alreadi demonstr
bioequival track first
us market much larger one gener avail
anoth like soon given demand shortag liposom
doxorubicin room anoth gener view repres
anoth opportun cytori
conclus cytori primari focu cell therapi habeo
repres signific upsid compani expect
continu advanc commerci partner come board would
signific catalyst compani
nanoparticl form doxorubicin demonstr bioequival reduc
cardiotox eu trial use js caelyx refer standard pegyl
liposom doxorubicin approv year ago patent open
opportun cytori enter gener version cytori prepar file
ema central eu approv breast ovarian cancer opportun
expand multipl myeloma kaposi sarcoma per eu procedur cytori
need demonstr stabil expect begin stabil test yield
preliminari result allow ema file prior final month
data posit approv launch next step us
demonstr bioequival fda-approv refer drug lipodox
eu bioequival data caelyx ovarian cancer patient
random ratio receiv one two treatment sequenc sequenc
receiv singl dose caelyx first cycl second cycl
sequenc patient receiv singl dose first cycl caelyx
second cycl wash-out period cycl cycl
confirm bioequival european sourc caelyx
gener like liposom dox bioequival must fall within rang
refer product closer mid-point better
regul focu part cytori rang
click full note
biolif continu grow come warrant
biolif receiv proce exercis common stock
warrant exercis price per share combin cash
balanc sheet compani cash compani
valuat risen past year near high-end
rang reach past week drive valuat
biolif biopreserv media product continu adopt cell
therapi space includ car-t biolif becom embed
cell therapi clinic commerci process expect cell therapi
continu grow valuat continu rise biolif posit
continu grow
guidanc recal manag recent updat guidanc upon
restat gross margin
oper expens
biolif current suppli custom biolif custom
move close market exampl kolon life scienc
nr receiv approv knee osteoarthr korea kite pharma acquir
gilead buy approv yescarta came octob car-t repres
signific growth across multipl vertic biolif media logist expertis
shipper repres best industri commerci product
repres annual revenu compani
right media cell storag ship cell therapi space continu
grow exponenti passag centuri cure act paradigm
shift car-t part drive billion new industri biolif
biopreserv media cold chain logist platform play critic role cell
therapi provid right media store cell ship
perfect condit get efficaci viabl product patient stabil
shelf-lif function recoveri cell use cell therapi paramount
deliv efficaci product cell may need maintain normotherm
bodi temperatur hypotherm cool frozen temperatur differ condit
requir special media maintain cell viabil recoveri biolif two lead
media product hypothermosol fr cool cryostor freez minim cell
tissu swell reduc damag free radic keep ion concentr
right low temperatur provid high energi food cell use stimul
recoveri warm back avoid acid damag inhibit apoptosi
necrosi net result cell product viabl maintain
click full note
clear emerg use treat acut
pluristem announc ind investig new drug applic
clear treat victim acut radiat exposur
event attack accid
part approv ind protocol cell provid
hour radiat exposur cell dose optimum dose select
base prior studi non-human primat
also evalu depart defens dod
support arm forc could expos radiat program
leverag uniqu properti cell fact
stimul cell growth upon damag radiat healthi subject
dod program explor administr cell hour
prior potenti exposur
conclus signific mileston pluristem compani
gain ind clearanc advanc emerg view
valid allogen cell therapi platform pluristem
continu advanc cell therapi late-stag trial ar
claudic hip fractu sever data-readout ahead next
month provid catalyst stock
acut exposur high level radiat involv sever potenti lethal
injuri bone marrow well organ system within bodi high
dose radiat destroy bone marrow abil produc white cell red cell
platelet without cell patient high risk death acut radiat
syndrom ar program report posit result phase ii-equival studi
non-human primat dose cells/kg result surviv
rate irradi non-human primat vs surviv rate untreat group plx-
increas cell level nhp expos radiat
critic factor mean determin level exposur radiat prior
treatment like requir enabl rapid treatment
larg popul case nuclear emerg
ind clear emerg use ind use cell emerg
use event radiat exposur attack accid clear plx-
cell dose provid hour follow acut exposur
cell describ demonstr signific increas surviv
expos popul enhanc recoveri blood cell given cell
stimul cell growth absenc damag safe administ
healthi subject could potenti expos high level radiat like
arm forc pluristem work dod evalu hour
prior exposur
move toward pivot studi compani discuss fda
sever government agenc clear path pivot studi pluristem
alreadi primat data human safeti data data may may
need file bla on-going upcom studi expect
next year model commerci direct sale us gov
june ye pivot trial view would expect move quickli pluristem
oper fda anim rule addit studi univers
indiana examin addit popul geriatr pediatr well
interact drug data year use support bla
click full note
estim price reiter buy
result strong key metric well
rais ep estim
adjust ebitda estim million million importantli
confid estim due credit qualiti
import success factor view remain stabl loan grown
rais price target base new estim
result summari enova report april revenu
million versu guidanc million ep versu guidanc
adjust ebitda million versu guidanc
million consensu million
data due materi season enova busi comparison
year-ago quarter typic meaning compar revenu rose
ratio net charge-off averag combin loan
gross margin versu
adjust ebitda margin versu
impact new custom flat gross margin attribut combin
higher origin origin rel high
percentag origin come new custom new custom
prior credit histori enova enova take bigger initi loan loss provis
loan loan repeat custom enova
posit credit perform therefor provis less cours new
custom drive posit long-term result one reason
reiter buy rate
regulatori outlook enova strong trend toward instal loan line
credit fewer single-pay loan enova sanguin impact
cfpb octob rule regard small dollar loan rule squar aim
single-pay loan time rule schedul becom effect month
single-pay loan could minim enova versu loan portfolio
present addit head cfpb indic cfpb might revisit
part rule
rais estim reflect strong perform
increas guidanc new guidanc revenu million
million ep
adjust ebitda million million new
ep estim new adjust ebitda estim
million million page updat earn model
rais price target base new estim
improv outlook regard on-line subprime competitor
 buy best close compar price target enova
price-to-earnings multipl would versu elev enova ev/
ebitda multipl would versu elev view premium
high reason reason premium high especi price-to-earnings
multipl expect first year posit net
incom elev wherea enova profit sinc format
inde enova far matur fintech on-line lender view
click full note
buy rate price target
kb strateg opportun reit acquir share wage
proxi fight elect two director annual meet may
read proxi materi file kb favor
director nomine agre e-commerce-resist
strategi kb critic strategi seek control
chang manag nonetheless believ elect kb
nomine could larg materi distract execut
strategi addit believ crux kb proxi fight
 cost gener manag compens particular
recent chang new long-term goal alreadi address
issu proxi fight elect kb nomine would like
serv creat disrupt
therefor view elect nomine win/win
sharehold disrupt execut strategi
proxi fight proxi fight battl neither control strategi rather
 costs/manag compens corpor govern
parti rais good point favor elect nomine
non-disrupt kb goal wage proxi fight larg
accomplish alreadi action new long-term goal
proactiv move proxi fight began case subsequ
say pay vote case nudg proxi fight
case taken follow measur past two year
hire independ compens consult chang chairman
compens committe given salari increas bonu payout ceo
cfo chang long-term equiti incent plan reduc size
award revis target establish five-year goal reduc
cost revenu versu median peer
burden smaller shorter-term leas key compon strategi
ad three new independ director increas gender ethnic age
profession divers reduc equiti compens new compens
structur replac cash compens
suffici view kb measur enumer
suffici view measur address everi one
kb concern go long way direct addit regard
new posit direct capabl improv without disrupt
maintain price target price target equat estim
core ffo view discount peer price target could
warrant account smaller rel size howev note compar
peer stronger growth profil e-
commerce-resist busi model pay much higher dividend
versu averag
reiter buy rate next four quarter expect dividend yield
stock price appreci price target
result estim total return
click full note
maxim analyst coverag univers
